produits : TG4001 teaser

TG4001

Target HPV-induced cancers (HPV-16, E6 & E7 + IL-2)

TG4001, an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 antigens.

We have selected typical papillomavirus sequences that code for these antigens and have incorporated them into the DNA of a viral vector (MVA). We have also introduced a gene that codes for a molecule (interleukin 2, IL-2) that will stimulate the immune system at the injection site.

TG4001 triggers a specific immune response that supports the recognition and destruction of cancer cells carrying the HPV viral antigens. This approach enables the body to destroy the tumours.

TG4001 in action

More information